All In MedTech

Device Trial Radar · NCT02345720

Effects of Multifocal Contact Lens on Ocular Tissue

Effects on Ocular Tissues of Vistakon® Investigational Multifocal Contact Lenses - Asian Population Study

Last checked: Nov 20, 2026Latest source record: Jun 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Dec 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Johnson & Johnson Vision Care, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 26, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the etafilcon - PVP (multi-focal)

Conditions

  • Visual Acuity

Interventions

  • etafilcon - PVP (multi-focal)Device

    The investigational contact lens must be worn at least six hours daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Upper Eye Lid Margin StainingTime frame: 30 days Post wear
  2. Limbal StainingTime frame: 30 Days Post Wear
  3. Corneal StainingTime frame: 30 Days Post Wear

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.